Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(7): e22862.
Published online 2011 July 27. doi:  10.1371/journal.pone.0022862
PMCID: PMC3144948

Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR

Neeraj Vij, Editor


New multifunctional drugs that target multiple disease-relevant networks offer a novel approach to the prevention and treatment of many diseases. New synthetic oleanane triterpenoids (SO), such as CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) and its derivatives, are multifunctional compounds originally developed for the prevention and treatment of inflammation and oxidative stress. However, the protein binding partners and mechanisms of action of these SO are not yet fully understood. Here we characterize the putative target profile of one SO, CDDO-Imidazolide (CDDO-Im), by combining affinity purification with mass spectroscopic proteomic analysis to identify 577 candidate binding proteins in whole cells. This SO pharmaco-interactome consists of a diverse but interconnected set of signaling networks; bioinformatic analysis of the protein interactome identified canonical signaling pathways targeted by the SO, including retinoic acid receptor (RAR), estrogen receptor (ER), insulin receptor (IR), janus kinase/signal transducers and activators of transcription (JAK/STAT), and phosphatase and tensin homolog (PTEN). Pull-down studies then further validated a subset of the putative targets. In addition, we now show for the first time that the mammalian target of rapamycin (mTOR) is a direct target of CDDO-Im. We also show that CDDO-Im blocks insulin-induced activation of this pathway by binding to mTOR and inhibiting its kinase activity. Our basic studies confirm that the SO, CDDO-Im, acts on a protein network to elicit its pharmacological activity.


Chronic diseases are now the prime cause of most pain and suffering in American society, as well as the largest financial burden in the health care system [1]. Their present treatment is often unsatisfactory. Multiple factors are now known to cause the initiation, as well as drive the progression, of chronic neurodegenerative, inflammatory, cardiovascular, metabolic, or neoplastic diseases [2][4]. Because of the intrinsic complexity of all of these diseases, we now need an innovative therapeutic approach that uses multifunctional pharmaceuticals to simultaneously target an array of pathogenetically relevant pathways, each of which contributes to disease progression [5]. Such “systems-based” therapeutics would have the marked advantage of subverting drug-resistance, improving efficacy, and reducing adverse side effects [5][6].

Over the past decade a series of synthetic triterpenoids based on the natural triterpenoid, oleanolic acid (OA) has been synthesized [7][9]. These synthetic oleanane triterpenoids (SO) are multifunctional and have antiproliferative [10][11], anti-angiogenic [12], anti-diabetic [13], pro-apoptotic [14][20], anti-inflammatory [10], [11], [21][23], and cytoprotective [24][25] activities. Furthermore, the SO have been successfully used to prevent and treat many chronic diseases in experimental animals, including cancer [10], [26][29], emphysema [30][31], macular degeneration [32], liver disease [33][34], neurodegenerative diseases [35][36] and nephrotoxicity [37] in both in vitro and in vivo models. The SO, CDDO-methyl ester (CDDO-Me, Bardoxolone methyl) is currently in late-stage clinical development for treatment of chronic kidney disease (diabetic nephropathy) [73].

In the development of second generation OA derivatives, two electrophilic Michael acceptor sites were incorporated in the A and C rings of OA to increase the reactivity of OA toward cellular targets [25], [38]. In cells SO mediate their potent pharmacological effects in part through interactions with cellular nucleophiles such as discrete, redox-sensitive sulfhydryl groups of cysteine (Cys) residues on proteins, via reversible Michael addition [7], [9], [25], [38][41]. Therefore, one may expect that SO should have many cellular protein binding partners, depending on cellular context and the nucleophilicity of specific cysteine residues in specific targets.

A few biologically important targets of SO have already been discovered. Activation of the KEAP1/Nrf2 pathway has been shown to be critical for many of the activities of both CDDO-Me and its close relative, CDDO-Imidazolide (CDDO-Im) [24], [25], [42]. However, the SO are known to modulate numerous pathways in cell culture and recently it was shown that many KEAP1/Nrf2-independent cell-signaling targets are also modulated following administration of CDDO-Im in vivo [43]. To date, no global study to identify the complete spectrum of binding partners of SO on a proteome-wide scale has been reported. Therefore, here we report the results of such a proteomics approach. We have utilized biotin tagged SO conjugates as chemical probes to affinity purify protein binding partners after treatment of cells in culture and have identified these proteins by LC-MS/MS. We report here the identification of 577 proteins to which a biotinylated probe binds. This approach also identified and validated binding partners which have previously been reported to be direct SO targets, including IKK, JAK1, PTEN and tubulin [39], [40], [44][45]. Our studies now show that the multi-functional SO, CDDO-Im, as expected, exerts its varied pharmacological actions by acting on large and diverse protein networks.

Materials and Methods


CDDO-Im, TP-154 and TP-304 have been described previously [14], [46][50], TP-304 is Compound 6 in Ref. 49. They were dissolved in DMSO, and controls containing equal volumes of DMSO (<0.1%) were included in all experiments. Sources of commercial reagents were: rabbit polyclonal antibodies against HO-1, Keap-1, tubulin and GAPDH, Santa Cruz Biotechnology; all other antibodies were from Cell Signaling Technology. Insulin, LY294002, Rapamycin and all other chemicals were obtained from Sigma.

Cell Culture

HEK293 and PC-3 cells were from ATCC, and maintained in DMEM (HEK293) or RPMI (PC-3), with 10% FBS and in 5% CO2. In some cases cells were plated and treated in culture media containing 1% horse serum. To measure proliferation, an MTT assay was performed as described previously [45].

Cell Lysis, Western Blotting and mTORC1 Immunoprecipitation

For Western blots, HEK293 cells were washed twice with cold PBS and suspended in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate (Na3VO4), 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 10 µmol/L leupeptin, and 5 µg/ml aprotinin). Protein concentration in centrifuged lysates was determined by Bradford assay. Lysates were immunoblotted as described previously [39]. Blots were developed with either pico-supersignal or femto-supersignal (Fisher Scientific). For mTORC1 immunoprecipitation [51], cells were washed twice with PBS and suspended in cold lysis buffer B (10 mM KPO4, pH 7.2, 0.3% CHAPS (to preserve the mTOR-Raptor interaction), 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM beta-glycerophosphate, 1 mM Na3VO4). Clarified lysate supernatants were incubated with anti-RAPTOR polyclonal antibodies for 2 h at 4°C, followed by incubation with protein A Sepharose beads for 2 h. Immunoprecipitates were washed three times in lysis buffer B, and resuspended in 50 µl of Laemmli loading buffer followed by immunoblotting with mTOR antibodies [52].

Biotinylated-Triterpenoid target affinity purification and Gel Staining for Proteomics

HEK-293 cells were plated in DMEM with 1% horse serum. The following day cells were treated with biotinylated SO as indicated for 1 h. Cells were then washed twice with cold PBS and lysed in Tris-HCl, 1% Triton X-100, pH 7.4 (Buffer A). Centrifuged lysates were incubated with 50 µl of MyOne™ Streptavidin T1 paramagnetic Dynabeads® (Invitrogen Corporation, Carlsbad, CA) for 1 h. Dynabead®-biotinylated triterpenoid protein-complexes were isolated magnetically and washed a total of five times with buffer A. An additional sample was treated with TP-304 and washed with a more stringent wash buffer (100 mM TrisHCl pH 7.4, 150 mM NaCl, 1% (v/v) Triton X-100, 300 mM sodium actate, 0.1% (v/v) SDS) to disrupt protein complexes and remove non-specific binding proteins. Complexes were boiled in Laemmli loading buffer and separated on 4–20% gradient, SDS-PAGE gels followed by staining overnight in a solution of 50% MeOH, 40% H2O, 10% acetic acid and 0.125% Coomassie brilliant blue R-250.

Sample preparation, MS and data anlysis

Coomassie-stained gels were divided into 8 regions and digested with trypsin overnight at room temperature. The next day, peptides were extracted, dried, and analyzed by nanoscale microcapillary LC-MS/MS as described. Samples were loaded using a FAMOS autosampler (LC Packings/Dionex, Sunnyvale CA) onto a custom manufactured reverse-phase, Reprosil-Pur 3 µm, 200 Å C18-AQ particle filled (Dr. Maisch GMBH, Ammerbuch-Entringen, Germany) fritless-tip microcapillary columns (0.125×180 mm, 7 µm tip) (Polymicro Technologies, Phoenix, AZ, and Sutter Instruments, Novato, CA) using an HPLC-driven (Agilent 1200 capLC) split-flow system designed to maintain 1200–1500 psi at the head of the analytical column. The resultant peptide eluate was directed into an LTQ-Orbitrap high performance mass spectrometer operating in a data-dependent sequencing acquisition mode across a 60-minute reverse-phase gradient (5% acetonitrile / 0.1% formic acid to 30% acetonitrile / 0.1% formic acid). The collected tandem mass spectra were data-searched using the SEQUEST algorithm [53], filtered to less than 1% false discovery rate using the target-decoy strategy [54] and reported.

Pathway analysis

For Go annotation, UniProt IDs were submitted to GORetriever [55] and categorized in GO_slim categories using CateGOrizer [56]. Overall connectivity of identified proteins was determined using STRING [57]. Highly connective subnetworks in the STRING network were identified using MCODE plug-in into Cytoscape [58]. For network analysis, UniProt IDs were submitted to Ingenuity software (Ingenuity® Systems,


Functional validation of biotinylated SO conjugates confirms their use as chemical probes

To identify candidate cellular targets of SO, biotinylated SO (btSO) conjugates have been synthesized. The pharmacological activity of these btSO was initially measured here by their ability to inhibit cellular proliferation (Figures 1a, 1b). Biotinylated TP-304 strongly inhibited proliferation of HEK293 cells, while TP-154 was completely inactive in this assay (Figure 1b). Furthermore we compared TP-154 and TP-304 with a potent, non-biotinylated, SO, CDDO-Im. We examined their ability to inhibit the activation of the NFκB pathway as induced by TNFα, by measuring their prevention of the degradation of IκBα (Figure 1c). CDDO-Im, blocks IκBα degradation, indicating that it prevents activation of the NFκB pathway (Figure 1c). Again, these results are also seen with TP-304, whereas the inactive TP-154 fails to prevent IκBα degradation. Based on these results TP-304 and TP-154 were selected for use in subsequent proteomic studies. TP-304 was used as a chemical probe to affinity purify target proteins, whereas TP-154 was used as an inactive negative control.

Figure 1
Characterization of SO for chemical proteomic studies.

Proteomics analysis reveals multiple SO binding proteins

Utilizing TP-304 and TP-154 as probes, we developed and optimized protocols to treat cells in culture for proteomic analysis. Because of the electrophilic nature of the SO and their ability to bind to redox active targets, it was important to ensure that the biotinylated probes interact with protein binding partners in their natural environment where the context-dependent nucleophilicity of -SH groups in cysteine residues is preserved. Following treatment with TP-304 and TP-154, both at 4 µM, for 1 h, HEK293 cells were lysed, and lysates were incubated with Neutravidin-coated Dynabeads to affinity purify protein targets (Figure 2a). Affinity purified proteins were separated on SDS-PAGE gels and stained with Coomassie blue (Figure 2b). Bands were excised, trypsinized and proteins identified by LC-MS/MS. The collected tandem mass spectra were data-searched using the SEQUEST algorithm [53] to identify target proteins. Following MS detection, proteins found in the TP-154 control sample were subtracted from proteins that were common to TP-304-treated samples, in both the normal and increased stringency wash conditions. (Figure 2a, 2b & 2c). 577 proteins common to both the TP-304 normal wash and the TP-304 high stringency wash were subjected to bioinformatic analysis (Figure 2c). A complete list of binding proteins is detailed in Figure S1.

Figure 2
Chemical proteomics studies for identification of SO targets.

The putative SO targets were annotated using gene ontology (GO) identifiers. For GO annotation, UniProt IDs were submitted to GORetriever and categorized in GO_slim categories using CateGOrizer. GO annotation based on molecular function showed that catalytic activity, protein kinase activity, transcription regulator activity, kinase activity and enzyme regulator activity represented 75% of putative TP-304 targets (Figure 3a). GO categorization of SO targets by biological process identified metabolism, transcription, development, cell cycle, and signal transduction to be the most prominent biological processes targeted by TP-304 (Figure 3b). While TP-304 bound to a large number of proteins, these proteins form a highly interconnected network. This overall connectivity map (or interactome) was established using the STRING database of known and predicted protein interactions, including direct (physical) and indirect (functional) associations (Figure 3c and 3d; high resolution images Figures S2 and S3). Interestingly, analysis of the STRING, SO-protein interaction network identified a subset of densely connected regions representing molecular complexes of interconnected sub-networks (Figure 3d). This sub-network contained clusters enriched with proteins involved in cell-cycle/cell division, meiosis/mitosis. This is not surprising given the potent anti-proliferative activities of the SO. Interestingly, central to these enriched clusters of proteins were a number of proteins that represent common signal transduction pathways critical for cell-cycle and cell division including PI3K/AKT/mTOR, JAK/STAT and BCR-ABL (Figure 3d). These data correlate with the findings from the gene ontology molecular function analysis which highlighted proteins involved in catalytic, kinase and transcription regulatory functions as being central targets of the SO in biological processes that include metabolism, transcription, cell cycle and signal transduction (Figures 3a and 3b).

Figure 3
Bioinformatic analysis of putative SO target proteins.

Thus we analyzed TP-304 targets using the Ingenuity software program to identify specific canonical pathways within the TP-304 binding partner dataset. This analysis identified a large number of canonical pathways targeted byTP-304 with very high significance (Figure 3e). The top 40 pathways are displayed in Figure 3e. While these analyses identified many new pathways with which CDDO-Im interacts, they also confirmed pathways for which the SO have previously been shown to modulate, including, janus kinase/signal transducers and activators of transcription (JAK/STAT), phosphatase and tensin homolog (PTEN), and AMP kinase (AMPK).

Validation of a subset of putative SO target proteins

Next we determined the validity of the putative SO binding partners identified in the above proteomics studies. We used methods previously employed to identify IKK as an SO target. HEK293 cells were treated with 4 µM TP-304 for 1 h, followed by lysis and pull-down of TP-304-protein binding partners with Neutravidin-coated agarose beads. Following a series of washes to eliminate nonspecific binding, the remaining bound proteins were eluted and separated by SDS-PAGE followed by Western blotting. This was performed for a subset of proteins specifically identified above (Figures 2c, ,3)3) by LC-MS/MS. As shown in Figure 4, we found that TP-304 bound specifically to 10 proteins, including protein kinase A, catalytic unit alpha (PKA-Cα) and beta (PKA-Cβ), ataxia telangiectasia and rad3 related (ATR), ataxia telangiectasia mutated (ATM), retinoid X receptor α (RXR-α), mammalian target of rapamycin (mTOR), AMP-dependent protein kinase (AMPK) (Figure 4); and IκB-kinase (IKK), c-Jun, and STAT1 (data not shown). These results in Figure 4 validate the MS approach taken in Figures 2 and and33 above.

Figure 4
Validation of putative SO targets identified by LC-MS/MS.

Functional validation of putative SO targets confirms mTOR as a direct SO target

The SO can bind to nucleophilic Cys residues on binding partners through Michael addition. Therefore, we sought to confirm that such binding had a functional effect on some of the binding partners identified above. We interrogated the Ingenuity-assigned canonical pathways to identify specific SO binding partners which appear in multiple pathways, and reasoned that proteins that appear in multiple canonical pathways may represent critical SO target nodes. Thus, components of the PI3K/AKT/mTOR pathway were highly enriched in our canonical dataset. We used the highly potent CDDO analog, CDDO-Im for these studies and found that it was a potent inhibitor of the phosphorylation of insulin-stimulated ribosomal S6 (RS6) at serine 235/236 (S235/236). As can be seen in Figure 5A, this phosphorylation of S235/236 is dose-dependently inhibited by CDDO-Im with complete inhibition observed at 250 nM. Importantly, the biotinylated SO, TP-304 also inhibited the phosphorylation of RS6 S235/236 (data not shown). Similarly, a second phosphorylation site on S6, serine 240/244 (S240/244) was also inhibited by the CDDO-Im (Figure 5A and data not shown). Levels of total RS6 remained unchanged upon SO treatment. We observed similar inhibition of the translational repressor protein 4E-BP1 at serine 37. As expected, these effects on RS6 and 4E-BP1 were also observed upon treatment with the mTOR inhibitor, rapamycin. Both 4E-BP1 and RS6 are critically important regulators of mitogen-induced mRNA translation levels in cells and are downstream targets of the phosphatidylinositol-3-OH kinase (PI3K) signal-transduction cascade which also includes the kinases AKT, mTOR and P70S6K [59].

Figure 5
CDDO-Im inhibits the autokinase activity of mTOR.

Thus, based on the observed enrichment for this pathway from our proteomics experiments and the observed inhibition of phosphorylation of both RS6 and 4E-BP1, we then investigated the effects of CDDO-Im on this pathway in greater detail in a hierarchical manner, beginning with RS6 and 4E-BP1 and working back up the pathway to determine at which level the CDDO-Im is inhibitory. Since P70S6 induces RS6 phosphorylation we looked at the insulin-induced activation of this important kinase. As expected, insulin rapidly induced phosphorylation of threonine 389 (T389) on P70S6K (Figure 5a). However, as observed with RS6 and 4E-BP1, CDDO-Im and rapamycin both prevented this activation, indicating that the inhibitory effects of the SO took place at a level above P70S6K activation. Since both P70S6K and 4E-BP1 are directly regulated by mTOR, and since mTOR and its binding partner, RAPTOR, were identified as direct targets for the SO in our proteomics screen we next examined whether the inhibitory effects of the SO on this pathway were mediated by disrupting the kinase activity of mTOR itself.

To examine the effects on mTOR in more detail we conducted an in-vitro mTOR activation assay which examines the phosphorylation levels of serine 2481 of mTOR [52]. Serine 2481 is an autophosphorylation site for this kinase [52]. mTORC1 was isolated by immunoprecipitating with anti-RAPTOR antibodies using a CHAPS-based lysis buffer which retains the integrity of the mTORC1 complex. Following immunoprecipitation, we immunoblotted with anti-mTOR S2481 antibodies to determine the level of phosphorylation at this autophosphorylation site. As can be seen in Figure 5b, in quiescent, serum-starved cells this site remains unphosphorylated but is rapidly phosphorylated (within 15 min) in response to insulin. This insulin-induced autophosphorylation is completely blocked by both rapamycin and CDDO-Im. Importantly, there was no effect on total mTOR levels immunoprecipitated by either rapamycin or CDDO-Im indicating that these treatments were not simply disrupting the mTOR-RAPTOR interaction. To further confirm the inhibition of mTOR in this experiment we performed Western blot experiments on whole cell lysates looking at phospho-P70S6K T389. As can be seen in Figure 5b, both rapamycin and CDDO-Im completely blocked autophosphorylation of P70S6K T389.

In order to exclude the possibility that the CDDO-Im was inactivating the pathway upstream of mTOR, and in turn blocking its activation we examined the activity of the upstream activating kinases, PI3K and AKT, by looking at phosphorylation levels of their substrates, AKT and GSK3β, respectively. As expected, we found that insulin rapidly phosphorylated AKT at S473 (Figure 5a). This effect was not blocked by either CDDO-Im or rapamycin, indicating that the CDDO-Im was not blocking activation of, or inhibiting PI3K, nor was it blocking activation of the mTOR complex 2 (mTORC2) which has recently been shown to phosphorylate AKT at S473. Again, these effects mimic that of rapamycin, which, under acute treatment conditions is unable to inhibit the activity of mTORC2. Furthermore, no effect was observed on phosphorylation of serine 9 of GSK3α/β (data not shown) indicating that activation or activity of AKT was not impaired by either CDDO-Im or Rapamycin (Figure 5a).

To determine if this inhibition of the mTOR signaling pathway was idiosyncratic to HEK293 cells we examined the effect of CDDO-Im in the prostate cell line, PC-3. PC-3 cells have constitutive activation of the PI3K/AKT/mTOR signaling axis due to mutations in the lipid phosphatase, PTEN, which dephosphorylates PI3K. In PC3 cells CDDO-Im inhibited the phosphorylation of RS6 S235/236 and 4E-BP1 S65 (Figure 5c), indicating the effects observed in the HEK293 cells were not unique to a single cell line.


Utilizing a novel, chemical proteomics approach, we have identified 577 proteins which interact with the biotinylated SO, TP-304, in cell culture. While some of these proteins had previously been identified, to date, this is the first report of a comprehensive and system-wide analysis of SO binding partners. As expected, a large number of new binding partners were identified, forming a large interconnected network of proteins that interact with SO. Many of the canonical pathways previously implicated as being targeted by SO, such as NFκB, JAK/STAT, PTEN and AMPK were found in this analysis [7], [32], [39], [40], [60][61].

In addition to these networks identified in silico, we have functionally validated the mTOR pathway as a target for CDDO-Im. Previous studies have suggested that this pathway may be inhibited by very high concentrations of the SO, CDDO-Me [62][63]. However, this is the first report to show that CDDO-Im also inhibits this pathway and also the first report that nanomolar concentrations of an SO directly inhibit the kinase activity of mTOR. mTOR belongs to a family of 6 kinases referred to as phosphoinositide-3-OH-kinase-related kinases (PIKKs). Interestingly the PIKK family members ATM and ATR and TRRAP were also pulled-down by TP-304.

The SO are extremely potent inhibitors of cellular proliferation [10][11]. The concentrations at which such inhibition is observed correlates with those we report for mTOR inhibition. Therefore, one may propose that this potent inhibition of proliferation may, in part, be due to inhibition of translation through disrupting mTOR activity. The identification of the PI3K/mTOR pathway as a central node in the STRING analysis interconnecting critical cell cycle and cell division proteins as well as the prominence of cell cycle proteins in the GO analysis would suggest this may be an important target for the SO. Also, it was recently reported that CDDO-Im alters microtubule dynamics by disrupting the microtubule-capping protein, Clip-170 which is an mTOR target protein [64]. Our observations suggest that the mechanism by which CDDO-Im disrupts Clip-170 may be through inhibition of the kinase activity of mTOR. Aberrant activation of mTOR and S6K has been shown to play a critical role in the development of diabetes and diabetic nephropathy [65][68]. Currently, CDDO-Me (Bardoxolone methyl) is undergoing late stage clinical development for the treatment of nephropathy in diabetes patients and significant improvements in markers of renal function have been reported [73]. Some of the improvements observed in these patients may be mediated through the inhibition of the mTOR/S6K signaling axis. Further studies toward this goal are ongoing in our laboratory.

One caveat of our proteomics-based target search is its qualitative nature, which lacks quantitative information about the SO-target interaction. Binding in such assays is a function of both protein/target abundance and affinity; therefore, highly abundant-low affinity proteins will co-purify with low abundance high-affinity proteins, making it difficult to infer relative affinities of the SO for the identified targets. However, multi-functional drugs typically bind to targets with lower affinity than a single target drug. Previous studies have suggested that low-affinity, multi-target drugs have a lower prevalence and a reduced range of side-effects than high-affinity, single-target drugs while also being more efficacious [7], [69][71]. By virtue of their low affinity binding, drugs of this type work best under pathological conditions, for the prevention of disease by restoring cellular homeostasis. Indeed it is in the area of chemoprevention that the SO have excelled in in vivo models. Currently the development of network-based, multi-target drugs similar in function to the SO is gaining increased interest in the field of drug development [7], [69][71]. Also, it should be noted that not all 577 proteins identified by MS analysis may be direct SO targets. It is possible that the lysis and wash conditions used did not completely disrupt high affinity protein complexes. We identified numerous proteins that are known to form high affinity complexes in cells including, but not limited to ATM/ATR and mTORC1. While this may cloud the identification of direct targets it facilitates the identification of protein complexes and pathways with which the SO interacts. One other caveat is the possibility that the coupling of the biotin group on the btSO may impede interactions with some target proteins. Indeed, TP-304 appears to have a lower affinity for KEAP1 (unpublished observation) which explains its absence from our list of proteins identified by MS. However, in spite of the above caveats, the data shown here open the way to new investigations that will examine the more difficult problem of interactions of SO with targets in real time.

In summary, technological advances in the integration of proteomics, pharmacology and molecular biology now provide the means to map drugs and targets at a systems level. Indeed, it has become evident that many drugs thought to specifically target a single protein, e.g. the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, are, in fact more promiscuous than originally thought [72]. Further advances in drug development, enhanced by an understanding of the genetic and epigenetic complexity of many chronic diseases, will come from drugs that target multiple components of critical signaling pathways and metabolic networks. In this regard, our studies demonstrate the utility of proteomic methods using biotinylated compounds as probes for identifying new candidate targets and perhaps may facilitate the use of SO in previously unrecognized therapeutic applications. The goals of targeting complex networks and applying systems biology to drug discovery are now of immediate importance.

Supporting Information

Figure S1

Complete list of protein TP-304 binding proteins identified by LC-MS/MS. The collected tandem mass spectra were data-searched using the SEQUEST algorithm, filtered to less than 1% false discovery rate using the target-decoy strategy as described in the materials and methods section. The list is presented in descending order of total peptides (T.P.) and unique peptides (U.P.)


Figure S2

High resolution, scalable image of the network map depicted in figure 3c.


Figure S3

High resolution, scalable image of the sub-network map depicted in figure 3d.



We thank Dr. Kathy Martin (Yale University School of Medicine, New Haven, CT) for helpful discussion and antibodies used in the mTOR studies and Dr. Diane Fingar (University of Michigan, Ann Arbor, MI) for sharing protocols for the mTORC1/mTOR autophosphorylation assay. TP-304 was generously provided by Reata Pharmaceuticals. We thank Charlotte Williams, Renee Risingsong and Darlene Royce for skilled technical assistance and Sarah Bisbee for assistance with the manuscript.


Competing Interests: Karen Liby and Michael Sporn are inventors on patents dealing with chemical synthesis of new triterpenoids and their application in treatment of cancer, as well as in inflammatory diseases, including human kidney disease (patent 6,974,801 issued 1/1/2004). They strongly adhere to the PLoS ONE policy on sharing of data and materials. The Sporn Laboratory has a long history of being extremely free in sharing of materials, with no strings attached, with other laboratories throughout the world.

Funding: These studies were supported by grants from the NIH (RO1 CA78814) and Reata Pharmaceuticals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. 2010.
2. Hidalgo CA, Blumm N, Barabasi A, Christakis NA. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol. 2009;5:e1000353. [PMC free article] [PubMed]
3. Shen Y, Liu J, Estiu G, Isin B, Ahn YY, et al. Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci U S A. 2010;107:1082–1087. [PubMed]
4. Park J, Lee DS, Christakis NA, Barabasi AL. The impact of cellular networks on disease comorbidity. Mol Syst Biol. 2009;5:262. [PMC free article] [PubMed]
5. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci. 2005;26:178–182. [PubMed]
6. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–690. [PubMed]
7. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 2007;7:357–369. [PubMed]
8. Sporn MB, Liby K, Yore MM, Suh N, Albini A, et al. Platforms and networks in triterpenoid pharmacology. Drug Development Research. 2007;68:174–182.
9. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury cause by inflammatory and oxidative stress. J Nat Prod. 2011;74:537–545. [PMC free article] [PubMed]
10. Place AE, Suh N, Williams CR, Risingsong R, Honda T, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003;9:2798–2806. [PubMed]
11. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999;59:336–341. [PubMed]
12. Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther. 2007;6:3139–3146. [PubMed]
13. Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem. 2010;285:40581–40592. [PubMed]
14. Liby K, Voong N, Williams CR, Risingsong R, Royce B, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res. 2006;12:4288–4293. [PubMed]
15. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005;65:4799–4808. [PubMed]
16. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004;64:7927–7935. [PubMed]
17. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004;103:3158–3166. [PubMed]
18. Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J Biol Chem. 2002;277:16448–16455. [PubMed]
19. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, et al. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol. 2001;59:1094–1099. [PubMed]
20. Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, et al. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ. 2000;11:261–267. [PubMed]
21. Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG, et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:4233–4246. [PubMed]
22. Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, et al. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:1866–1877. [PubMed]
23. Suh N, Honda T, Finlay HJ, Barchowsky A, Williams C, et al. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 1998;58:717–723. [PubMed]
24. Liby K, Hock T, Yore MM, Suh N, Place AE, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005;65:4789–4798. [PubMed]
25. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A. 2005;102:4584–4589. [PubMed]
26. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007;67:2414–2419. [PubMed]
27. Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, et al. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res. 2008;14:4556–4563. [PubMed]
28. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther. 2008;7:1251–1257. [PubMed]
29. Liby K, Risingsong R, Royce DB, Williams CR, Ma T, et al. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res. 2009;2:1050–1058. [PMC free article] [PubMed]
30. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuatescigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A. 2009;106:250–255. [PubMed]
31. Reddy NM, Suryanaraya Y, Yates MS, Kleeberger SR, Hassoun PM, et al. The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. Am J Respir Crit Care Med. 2009;180:867–874. [PMC free article] [PubMed]
32. Cano M, Thimmalappula R, Fujihara M, Nagai N, Sporn M, et al. Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and age-related macular degeneration. Vis Res. 2010;50:652–664. [PMC free article] [PubMed]
33. Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res. 2006;66:2488–2494. [PubMed]
34. Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, et al. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci. 2008;104:218–227. [PMC free article] [PubMed]
35. Stack C, Ho D, Wille E, Calingasan NY, Williams C, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med. 2010;49:147–158. [PMC free article] [PubMed]
36. Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE. 2009;4:e5757. [PMC free article] [PubMed]
37. Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes - Nrf2, PPARy, and HO-1. Am J Physiol Renal Physiol. 2011;300:1180–1192. [PubMed]
38. Couch RD, Browning RG, Honda T, Gribble GW, Wright DL, et al. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem Lett. 2005;15:2215–2219. [PubMed]
39. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther. 2006;5:3232–3239. [PubMed]
39. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther. 2006;5:3232–3239. [PubMed]
40. Ahmad R, Raina D, Meyer C, Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res. 2008;68:2920–2926. [PMC free article] [PubMed]
41. Na HK, Surh YJ. Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol Carcinog. 2006;45:368–380. [PubMed]
42. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 2007;6:154–162. [PubMed]
43. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis. 2009;30:1024–1031. [PMC free article] [PubMed]
44. Couch RD, Ganem NJ, Zhou M, Popov VM, Honda T, et al. 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: a possible mechanism contributing to apoptosis. Mol Pharmacol. 2006;69:1158–1165. [PubMed]
45. Pitha-Rowe I, Liby K, Royce D, Sporn M. Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest Ophthalmol Vis Sci. 2009;50:5339–5347. [PubMed]
46. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, et al. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett. 1998;8:2711–2714. [PubMed]
47. Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, et al. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:1866–1877. [PubMed]
48. Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG, Jr, et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:4233–4246. [PubMed]
49. Honda T, Janosik T, Honda Y, Han J, Liby KT, et al. Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. J Med Chem. 2004;47:4923–4932. [PubMed]
50. Honda T, Honda Y, Favaloro FG, Gribble GW, Suh N, et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett. 2002;12:1027–1030. [PubMed]
51. Acosta-Jaquez HA, et al. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol. 2009;29:4308–4324. [PMC free article] [PubMed]
52. Soliman GA, Keller JA, Foster KG, Ekim B, Soliman GA, et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem. 2010;285:7866–7879. [PubMed]
53. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 1999;17:676–682. [PubMed]
54. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in largescale protein identifications by mass spectrometry. Nat Methods. 2007;4:207–214. [PubMed]
55. McCarthy FM, Wang N, Magee GB, Nanduri B, Lawrence ML, et al. AgBase: a functional genomics resource for agriculture. BMC Genomics. 2006;7:229. [PMC free article] [PubMed]
56. Hu ZL, Bao J, Reecy JM. CateGOrizer: A Web-Based Program to Batch Analyze Gene Ontology Classification Categories. Online J Bioinformatics. 2008;8:108–112.
57. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37:D412–D416. [PMC free article] [PubMed]
58. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504. [PubMed]
59. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619. [PubMed]
60. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006;281:35764–35769. [PubMed]
61. Shishodia S, Sethia G, Konopleva M, Andreeff M, Aggarwal BB, et al. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through downregulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res. 2006;12:1828–1838. [PubMed]
62. Deeb D, Gao X, Jiang H, Dulchavsky SA, Gautam SC. Oleanane triterpenoid CDDOMe inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate. 2009;69:851–860. [PubMed]
63. Gao X, Deeb D, Hao J, Liu Y, Arbab AS, et al. Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-kappaB signaling proteins in colorectal cancer cells. Anticancer Res. 2010;30:785–792. [PubMed]
64. To C, Kulkarni S, Pawson T, Honda T, Gribble GW, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex. J Biol Chem. 2008;283:11700–11713. [PubMed]
65. Zoncu R, Efeyan A, Sabatani DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35. [PMC free article] [PubMed]
66. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009;20:2493–2502. [PubMed]
67. Inoki K. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract. 2008;82(Suppl 1):S59–S62. [PubMed]
68. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 384:471–475. [PubMed]
69. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol. 2006;16:127–136. [PubMed]
71. Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25:1110–1111. [PubMed]
72. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49:615–619. [PubMed]
73. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33:469–476. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science